Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 33, 2022 - Issue 4
Submit an article Journal homepage
435
Views
11
CrossRef citations to date
0
Altmetric
Letters

Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes

J. S. Westerdahla School of Medicine, University of Utah, Salt Lake City, UT, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3861-9955
ORCID Icon,
K. B. Nusbaumb College of Medicine, University of Cincinnati, Cincinnati, OH, USA
,
C. G. Chungc Division of Dermatology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA;d Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USA
,
B. H. Kaffenbergerc Division of Dermatology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA
&
A. G. Ortega-Loayzae Department of Dermatology, Oregon Health and Science University, Portland, OR, USA
Pages 2386-2390 | Received 05 May 2021, Accepted 25 May 2021, Published online: 14 Jun 2021

Resources

  • Herberger K, Dissemond J, Brüggestrat S, et al. Biologics and immunoglobulins in the treatment of pyoderma gangrenosum – analysis of 52 patients. J Dtsch Dermatol Ges. 2019;17:32–41.
  • Wu J, Smogorzewski J. Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases. Dermatol Ther [Internet]. 2021.
  • Fahmy M, Ramamoorthy S, Hata T, et al. Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol. 2012;107(5):794–795.
  • Guenova E. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol. 2011;147(10):1203.
  • Petty AJ, Whitley MJ, Balaban A, et al. Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab. JAAD Case Rep. 2020;6(8):731–733.
  • Low ZM, Mar A. Treatment of severe recalcitrant pyoderma gangrenosum with ustekinumab. Australas J Dermatol. 2018;59(2):131–134.
  • Nieto D, Sendagorta E, Rueda JM, et al. Successful treatment with ustekinumab and vacuum-assisted closure therapy in recalcitrant myelodysplastic syndrome-associated pyoderma gangrenosum: case report and literature review. Clin Exp Dermatol. 2019;44(1):116–119.
  • Benzaquen M, Monnier J, Beaussault Y, et al. Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: effectiveness of ustekinumab. Australas J Dermatol. 2017;58(4):e270–e271.
  • Cosgarea I, Lovric Z, Körber A, et al. Successful treatment of refractory pyoderma gangrenosum with ustekinumab only after excision of renal cell carcinoma. Int Wound J. 2016;13(5):1041–1042.
  • Greb JE, Gottlieb AB, Goldminz AM. High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum. Dermatol Ther. 2016;29(6):482–483.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.